These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8738056)

  • 61. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
    Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
    Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vital indication for erythropoietin in a chronic haemodialysis patient. A case report.
    Nielsen OJ; Thaysen JH
    Dan Med Bull; 1989 Dec; 36(6):590-2. PubMed ID: 2612227
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients.
    Lebel M; Kingma I; Grose JH; Langlois S
    J Am Soc Nephrol; 1998 Jan; 9(1):97-104. PubMed ID: 9440093
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Does chronic oral treatment with beta-receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?].
    Günnicker M; Brinkmann M; Freund U; Piotrowski J; Schieffer M; Velser U
    Herz; 1995 Dec; 20(6):399-411. PubMed ID: 8582699
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effect of recombinant human erythropoietin on the bone marrow picture in patients with chronic renal failure treated by hemodialysis].
    Sułowicz W; Hanicki Z; Skotnicki AB; Wójcik J; Sydor A
    Przegl Lek; 1992; 49(3):88-90. PubMed ID: 1438902
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiovascular effects of increasing hemoglobin in chronic renal failure.
    Mayer G; Hörl WH
    Am J Nephrol; 1996; 16(4):263-7. PubMed ID: 8739276
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Folic acid supplementation improves erythropoietin response.
    Pronai W; Riegler-Keil M; Silberbauer K; Stockenhuber F
    Nephron; 1995; 71(4):395-400. PubMed ID: 8587618
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure.
    Metra M; Cannella G; La Canna G; Guaini T; Sandrini M; Gaggiotti M; Movilli E; Dei Cas L
    Am J Cardiol; 1991 Oct; 68(10):1060-6. PubMed ID: 1927920
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients.
    Collart FE; Dratwa M; Wittek M; Wens R
    ASAIO Trans; 1990; 36(3):M219-23. PubMed ID: 2147556
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 74. [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis].
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Solarska K
    Pol Arch Med Wewn; 1991 Jun; 85(6):352-5. PubMed ID: 1716757
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
    Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
    Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dialysis dose, membrane type, and anemia control.
    Young EW
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impaired erythrocyte fluidity during treatment of renal anaemia with erythropoietin.
    Linde T; Sandhagen B; Danielson BG; Wikström B
    J Intern Med; 1992 Jun; 231(6):601-6. PubMed ID: 1619383
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.